OpenEvidence vs ChatGPT for clinicians: which is better for clinical questions

For clinical questions, yes, and the reason is architectural rather than a matter of one model being smarter. OpenEvidence answers by retrieving from the published literature and showing you the citations, so the answer arrives with a paper trail you can open and judge. ChatGPT answers from a general model, and unless you have explicitly put it in a mode that searches and cites, what you get is a fluent statement with nothing behind it that you can check in one click.

That distinction matters most exactly where clinicians are most tempted to skip it. A general assistant is confident about a drug dose in the same tone it uses for a restaurant recommendation, and there is no visible difference between the sentence it got right and the sentence it assembled. When the question is clinical, the ability to open the source is not a nicety, it is the whole safety mechanism.

Where ChatGPT wins is everything that is not a clinical fact. Rewriting a referral letter, turning a messy protocol into a table, summarizing a long document, working through the logic of a scheduling problem: it is genuinely better at that than a tool built to answer clinical questions, and most clinicians end up using both for different halves of the day.

It will answer the question, which is not the same as checking. There is no drug interaction database underneath a general assistant, so what you get is the model reproducing what it has read about that drug pair, with no structured cross-check against a maintained clinical dataset and no guarantee it has considered the other seven drugs on the list. It is often right about the famous pairs and much weaker on the ones that actually get missed.

The failure mode is quiet. A general model tends to confirm the interaction you asked about and say nothing about the one you did not think to ask about, and missed interactions are overwhelmingly the ones nobody thought to check. A tool that runs the full check on a medication list behaves differently: it surfaces the flag you were not looking for. If you want that behavior, use a real drug interaction checker rather than a chat window.

The same caution applies to renal dosing, pediatric dosing and contraindications. A general assistant can describe the principle well. It should not be the last thing between your judgment and a signature.

Not in the form most clinicians use it. HIPAA compliance for a vendor turns on whether they will sign a Business Associate Agreement, and OpenAI's published guidance is specific about which products qualify: a BAA is available for ChatGPT Enterprise and ChatGPT Edu on sales-managed accounts, and for the API platform on request, and OpenAI states plainly that it does not offer a BAA for ChatGPT Business. The consumer tiers, Free and Plus, are not covered either.

So the practical answer for an individual clinician typing into ChatGPT on their own account is that no BAA exists, which means protected health information should not go into the box. That is not a comment on OpenAI's security, which is substantial. It is a contractual gap, and HIPAA cares about the contract.

There is one more detail worth knowing if your organization is going the API route: the BAA covers only endpoints eligible for zero data retention. That is the kind of clause that decides an architecture, and it is easier to read before you build than after.

OpenEvidence says so directly. Its announcement of 25 April 2025 states that OpenEvidence "now fully complies with the requirements of the Health Insurance Portability and Accountability Act (HIPAA)" and that "U.S. covered entities can securely input protected health information (PHI) in accordance with HIPAA's privacy and security standards", handled under its Business Associate Agreement. That is a clear, dated, vendor-published position, and it is more than most clinical AI tools have put in writing.

The nuance that gets lost is who the agreement covers. A vendor BAA protects the covered entity that has one. An individual clinician using the tool on a personal account is not automatically inside their employer's compliance perimeter, and OpenEvidence's own materials put the responsibility for lawful inputs back on the user.

Health systems have read it that way too. MaineHealth tells its clinicians in writing that they should not submit PHI or other sensitive data in OpenEvidence queries, noting that it has not reached acceptable BAA terms with the vendor and that a personal agreement does not protect the organization's data. Both things are true at once: the vendor is HIPAA-capable, and your employer may still forbid it. Check your own policy before you assume the vendor's announcement covers you.

Advertising, aimed at a verified clinical audience. Pharmaceutical and other healthcare advertisers pay to reach clinicians who have proved they are clinicians, and that funds free access at the point of use. There is no paywall a few questions in, and the free tier is not a trial. We go through the model and its trade-offs in more detail in is OpenEvidence free.

The honest caveat is the incentive rather than a hidden fee. Promotional content shares the page with clinical answers, and clinicians differ on how comfortable that makes them. It is also worth knowing that the company withdrew from the EU and the UK in 2026, citing the EU AI Act and regulatory uncertainty, so access outside the US is not something to plan around.

The comparison lands the same way. Claude, Gemini, Grok and the rest are general assistants: strong at reasoning and writing, not built on a clinical database, and governed by whatever BAA their vendor does or does not offer for the specific tier you are using. Some of them cite sources well when asked. None of them is a substitute for a tool whose entire job is to retrieve and cite clinical literature, and none should be the last check before a signature.

The useful mental model is three layers rather than a contest. General assistants handle the language work. A clinical answer engine handles the evidence question. A prescribing check runs the interactions, contraindications and dose adjustments for the specific patient picture. Trying to make one layer do all three is where clinicians get into trouble, and it is also why AI clinical decision support built for prescribing is a different product category from a chat window.

Both wait to be asked. Neither watches the prescription in front of you and tells you, unprompted, that the patient is already on something that interacts with it, that their renal function makes the standard dose wrong, or that a documented allergy rules out the obvious choice. To get that from an answer engine you have to think to ask, several separate times, on an afternoon that is already running late. The checks that get skipped are the ones nobody thought to run.

Prescriber.io collapses that into one step. Enter the drug or the scenario once and it checks drug-drug interactions, flags contraindications and allergy blockers, surfaces renal and hepatic dose adjustments and suggests guideline-based alternatives, together, in a single card with cited sources. It is decision support for licensed clinicians, not autonomous prescribing. You review every flag, verify against official sources, and sign. If you also want a head-to-head against a traditional reference, see UpToDate vs OpenEvidence.